Revance Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVNC research report →
Companywww.revance.com
Revance Therapeutics, Inc. , a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
- CEO
- Mark J. Foley
- IPO
- 2014
- Employees
- 597
- HQ
- Nashville, TN, US
Price Chart
Valuation
- Market Cap
- $381.02M
- P/E
- -0.95
- P/S
- 1.63
- P/B
- -2.04
- EV/EBITDA
- -2.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 34.98%
- Op Margin
- -135.35%
- Net Margin
- -138.43%
- ROE
- 466.15%
- ROIC
- -79.18%
Growth & Income
- Revenue
- $234.04M · 76.55%
- Net Income
- $-323,986,000 · 9.10%
- EPS
- $-3.83 · 21.84%
- Op Income
- $-316,777,000
- FCF YoY
- -3.19%
Performance & Tape
- 52W High
- $7.56
- 52W Low
- $2.30
- 50D MA
- $3.39
- 200D MA
- $4.16
- Beta
- 0.95
- Avg Volume
- 2.96M
Get TickerSpark's AI analysis on RVNC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 4, 25 | Gangolli Julian S | other | 30,106 |
| Feb 6, 25 | Gangolli Julian S | sell | 15,000 |
| Feb 6, 25 | Foley Mark J | other | 84,686 |
| Feb 4, 25 | Foley Mark J | other | 996,935 |
| Feb 4, 25 | Foley Mark J | other | 110,913 |
| Feb 6, 25 | Foley Mark J | sell | 84,686 |
| Feb 4, 25 | Schilke Tobin | other | 97,999 |
| Feb 6, 25 | Schilke Tobin | other | 20,883 |
| Feb 6, 25 | Schilke Tobin | sell | 20,883 |
| Feb 4, 25 | Moxie Dwight | other | 47,815 |
Our RVNC Coverage
We haven't published any research on RVNC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RVNC Report →